Cancer Biomarkers in Precision Medicine March 6-8, 2018

Bethesda North Marriott Hotel & Conference Center Bethesda, Maryland

Tuesday,	March	6.	2018
I ucsuay,	match	\mathbf{v}	2010

7:00 a.m. – 8:00 a.m. <i>Ballroom Foyer</i>	Registration
8:00 a.m 12:00 p.m. Salon F-H	Early Detection Research Network (EDRN) and Food and Drug Administration (FDA) Workshop on Diagnostic Biomarkers
8:00 a.m 8:10 a.m.	Welcome and Charge to Participants Sudhir Srivastava, Ph.D., M.P.H., National Cancer Institute Kelly Oliner, Ph.D., Deputy Division Director, OIR/DIHD, FDA
8:10 a.m 9:00 a.m.	Discussion Topic: Establishing a pathway for investigators for an FDA pre-submission on proposed design(s) for prospective early detection and/or diagnostic studies - without necessarily having an industry partner.
8:10 a.m. – 8:20 a.m.	FDA Pre-submission Process - Overview
8:20 a.m. – 8:35 a.m.	Steven Skates, Ph.D., Massachusetts General
8:35 a.m. – 8:50 a.m.	Hospital Jeffrey Seidman, M.D., Medical Officer, OIR/DMGP Anand Pathak, M.D., Ph.D., M.P.H., Medical Officer, OIR/DMGP
8:50 a.m. – 9:00 a.m.	Discussion
9:00 a.m. – 9:50 a.m.	Discussion Topic: Exploration of the use of banked samples from large cohorts, such as WHI and PLCO, for submission to FDA for claims of early detection.
9:00 a.m. – 9:15 a.m.	David Ransohoff, M.D., University of North
9:15 a.m. – 9:35 a.m.	Carolina at Chapel Hill Gene Pennello, Ph.D., Team Leader, Biostatistics, OSB/DBS, FDA
9:35 a.m. – 9:50 a.m.	Discussion
9:50 a.m 10:10 a.m.	Break

Cancer Biomarkers in Precision Medicine March 6-8, 2018

Bethesda North Marriott Hotel & Conference Center Bethesda, Maryland

Tuesday, March 6, 2018 Continued

EDRN and FDA Workshop on Diagnostic Biomarkers Continued

10:10 a.m. – 11:00 a.m. Salon F-H	Discussion Topic: FDA requirements for technology platform approval/clearance, with a focus on proteomics and mass spectrometry.
10:10 a.m. – 10:25 a.m. 10:25 a.m. – 10:45 a.m.	Daniel Chan, Ph.D., Johns Hopkins University Doug Jeffery, Ph.D., Branch Chief, OIR/DIHD/IMFB, FDA
10:45 a.m. – 11:00 a.m.	Discussion
11:00 a.m 11:50 a.m.	Discussion Topic: FDA requirements for analyte approval/clearance (analyte panel and classifiers).
11:00 a.m. –11:15 a.m.	
11:15 a.m. –11:35 a.m.	Zhen Zhang, Ph.D., Johns Hopkins University Aaron Schetter, Ph.D., M.P.H., OIR, DMPG, FDA

12:00 p.m.

Adjourn

FDA Participants

Reena Philip, Ph.D., Division Director OIR/DMGP
Lea Carrington, MS, MBA, MT (ASCP), Division Director OIR/DIHD
Kelly Oliner, Ph.D., Deputy Division Director, OIR/DIHD
Meijuan Li, Ph.D., Branch Chief, OSB/DBS
Eunice Lee, Ph.D., Branch Chief, OIR/DMGP
Doug Jeffery, Ph.D., Branch Chief, OIR/DIHD
Gene Pennello, Ph.D., Team Leader, Biostatistics, OSB/DBS
Changhong Song, Ph.D., Team Leader, Biostatistics, OSB/DBS
Anand Pathak, M.D., Ph.D., M.P.H., Medical Officer, OIR/DMGP
Jeffrey Seidman, M.D., Medical Officer, OIR/DMGP
Majda Haznadar, Ph.D., Scientific Reviewer, OIR/DMGP

OIR: Office of In Vitro Diagnostics and Radiological Health

DMGP: Division of Molecular Genetics and Pathology

DIHD: Division of Immunology and Hematology

OSB: Office of Surveillance and Biometrics

DBS: Division of Biostatistics

Cancer Biomarkers in Precision Medicine March 6-8, 2018

Bethesda North Marriott Hotel & Conference Center Bethesda, Maryland

12:00 p.m. – 1:00 p.m.	EDRN Executive Committee Meeting (closed
	• •

White Oak B session)

8:00 a.m. - 1:00 p.m. Registration

Ballroom Foyer

1:00 p.m. - 1:10 p.m. Welcoming Remarks

Salon F-H Barnett S. Kramer, M.D., M.P.H., Director, Division of Cancer Prevention, National Cancer

Institute

1:10 p.m. - 1:15 p.m. Welcome and Charge to Participants

Sudhir Srivastava, Ph.D., M.P.H., National

Cancer Institute

1:15 p.m. – 1:20 p.m. Network Consulting Team's Perspective on

the EDRN

Larry Norton, M.D., Chair EDRN Network Consulting Team, Memorial Sloan Kettering

Cancer Center

1:20 p.m. - 1:45 p.m. Plenary Lecture

Impressions of a New NCI Director

Norman Sharpless, M.D., Director, National

Cancer Institute

1:45 p.m. − 1:50 p.m. Q&A

1:50 p.m. – 3:40 p.m. <u>Session I: Innovative and Novel</u>

Technologies

Session Chairs

o Chair: Scott Tomlins, M.D., Ph.D.,

University of Michigan

o Co-Chair: Joshua LaBaer, M.D., Ph.D., Arizona State University/The Biodesign

Institute

 $1:50 \ p.m. - 1:55 \ p.m.$ Introduction to Session

Chair/Co-Chair

Cancer Biomarkers in Precision Medicine March 6-8, 2018

Bethesda North Marriott Hotel & Conference Center Bethesda, Maryland

Tuesday, March 6, 2018 Continued

Session I: Innovative and Novel Technologies Continued

1:55 p.m. – 2:20 p.m. Salon F-H	Plenary Lecture A Review of Seed Investments at the Knight Cancer Institute for Early Detection Research Sadik Esener, Ph.D., Oregon Health & Science University's Knight Cancer Institute
2:20 p.m. – 2:25 p.m.	Q&A
2:25 p.m. – 2:45 p.m.	<u>Liquid Biopsy for the Earlier Detection of Cancer</u> Kenneth Kinzler, Ph.D., Johns Hopkins University
2:45 p.m. – 2:50 p.m.	Q&A
2:50 p.m. – 3:10 p.m.	Multiplex Screening and Evaluation of Plasma Protein Biomarkers for Early detection of Colorectal Cancer Using Proximity Extension Assay Ida Grundberg, Ph.D., Olink Proteomics
3:10 p.m. – 3:15 p.m.	Q&A
3:15 p.m. – 3:35 p.m.	Biomarker Quantification by Compensated Interferometry: Lowering the LOQ to Improve Case-Control Separation for IPNs Darryl Bornhop, Ph.D., Vanderbilt University
3:35 p.m. – 3:40 p.m.	Q&A
3:40 p.m 4:00 p.m.	Break
4:00 p.m. – 5:50 p.m. Salon F-H	 Session II: Accelerating Validation and Implementation of Biomarkers Session Chairs Chair: John Wei, M.D., University of Michigan Co-Chair: Anirban Maitra, M.B.B.S., The University of Texas MD Anderson Cancer Center

Cancer Biomarkers in Precision Medicine March 6-8, 2018

Bethesda North Marriott Hotel & Conference Center Bethesda, Maryland

Tuesday, March 6, 2018 Continued

Session II: Accelerating Validation and Implementation of Biomarkers Continued

Introduction to Session Chair/Co-Chair
Plenary Lecture The Continuum of Risk Assessment and Early Detection through Blood Based Biomarkers Samir Hanash, M.D., Ph.D., The University of Texas MD Anderson Cancer Center Q&A
By Design Approach in Biomarker Development, Validation, and Clinical Implementation Zhen Zhang, Ph.D., Johns Hopkins University Q&A
Challenges in Moving Biomarkers from Bench to Bedside John Wei, M.D., University of Michigan
Q&A From Bench to Boardroom to Bedside: an Airway Gene-expression Biomarker's Journey Avrum Spira, M.D., M.Sc., Boston University
Q&A Adjourn for the Day

Cancer Biomarkers in Precision Medicine March 6-8, 2018

Bethesda North Marriott Hotel & Conference Center Bethesda, Maryland

Wednesday, March 7, 2018

7:00 a.m. – 8:00 a.m. <i>Ballroom Foyer</i>	Registration
8:00 a.m. – 10:15 a.m. Salon F-H	 Session III: Precision Detection of Early Stage Cancers Session Chairs Chair: Amanda Paulovich, M.D., Ph.D., Fred Hutchinson Cancer Research Center Co-Chair: Kenneth Kinzler, Ph.D., John Hopkins University
8:00 a.m. – 8:05 a.m.	Introduction to Session Chair/Co-Chair
8:05 a.m. – 8:30 a.m. 8:30 a.m. – 8:35 a.m.	Plenary Lecture Genomic Studies of Advanced and Early Lung Cancer Matthew Meyerson, M.D., Ph.D., Dana-Farber Cancer Institute Q&A
8:35 a.m. – 8:55 a.m. 8:55 a.m. – 9:00 a.m.	Biomarker Driven Non-Endoscopic Early Detection for Barrett's Esophagus Sanford Markowitz, M.D., Ph.D., Case Western Reserve University Q&A
9:00 a.m. – 9:20 a.m. 9:20 a.m. – 9:25 a.m.	Proteomic and Genomic Ovarian Cancer Biomarker Discovery and Validation Steven Skates, Ph.D., Massachusetts General Hospital Q&A
9:25 a.m. – 9:45 a.m.	Early Detection of Pancreatic Cancer through the Evaluation of Pancreatic Cysts Aatur Singhi, M.D., Ph.D., University of Pittsburgh
9:45 a.m. – 9:50 a.m.	Q&A

Cancer Biomarkers in Precision Medicine March 6-8, 2018

Bethesda North Marriott Hotel & Conference Center Bethesda, Maryland

Wednesday, March 7, 2018 Continued

Session III: Precision Detection of Early Stage Cancers

9:50 a.m. – 10:10 a.m. Salon F-H 10:10 a.m. – 10:15 a.m.	Prostate Cancer as a Model for the Challenges of Precision Early Detection Scott Tomlins, M.D., Ph.D., University of Michigan Q&A
10:15 a.m. – 11:30 a.m. Salon E	Poster Viewing Session 1
11:30 a.m 12:30 p.m.	Lunch Break (On Your Own)
11:30 a.m. – 12:30 p.m. White Oak B	Pancreatic Cancer Investigator Meeting (Closed Session)
12:30 p.m. – 3:10 p.m. Salon F-H	 Session IV: Imaging and Early Detection Session Chairs Chair: Eugene Koay, M.D., Ph.D., The University of Texas MD Anderson Cancer Center Co-Chair: Pierre Massion, M.D., Vanderbilt- Ingram Cancer Center
12:30 p.m. – 12:35 p.m.	Introduction to Session Chair/Co-Chair
12:35 p.m. – 1:00 p.m. 1:00 p.m. – 1:05 p.m.	Plenary Lecture High and Low Neuroendocrine Subtypes of Small Cell Lung Cancer and their Clinical Importance Adi Gazdar, M.D., University of Texas Southwestern Q&A
1:05 p.m. – 1:25 p.m. 1:25 p.m. – 1:30 p.m.	Habitat Risk Score in Prostate Cancer - Correlation with Histopathology from Radical Prostatectomy Radka Stoyanova, Ph.D., University of Miami Q&A

Cancer Biomarkers in Precision Medicine March 6-8, 2018

Bethesda North Marriott Hotel & Conference Center Bethesda, Maryland

Wednesday, March 7, 2018 Continued

Session IV: Imaging and Early Detection Continued

3:10 p.m. – 4:00 p.m. <i>Salon E</i>	Poster Viewing Session 2
3:05 p.m. – 3:10 p.m.	Center Q&A
2:45 p.m. – 3:05 p.m.	Radiomics Robert Gillies, Ph.D., H. Lee Moffitt Cancer
2:40 p.m. – 2:45 p.m.	Breast Cancers Victoria Seewaldt, M.D., City of Hope Q&A
2:20 p.m. – 2:40 p.m.	Strategies to Provide Temporal/Spatial High- resolution Mapping of Biologically Aggressive
2:15 p.m. – 2:20 p.m.	Detection of Cancer Eugene Koay, M.D, Ph.D., The University of Texas MD Anderson Cancer Center Q&A
1:55 p.m. – 2:15 p.m.	Multi-parametric Image Processing for Early
Salon F-H 1:50 р.т. – 1:55 р.т.	Denise Aberle, M.D., University of California, Los Angeles Q&A
1:30 p.m. – 1:50 p.m. Salon F-H	<u>Feature Characterization of Indeterminate Lung</u> Nodules

Cancer Biomarkers in Precision Medicine March 6-8, 2018

Bethesda North Marriott Hotel & Conference Center Bethesda, Maryland

Wednesday, March 7, 2018 Continued

4:00 p.m. – 5:30 p.m . Salon F-H	Session V: Building Alliances with Other Consortia Session Chairs Chair: Karen Anderson, M.D., Ph.D., Arizona State University Co-Chair: Denise Aberle, M.D., University of California, Los Angles
4:00 p.m. – 4:05 p.m.	Introduction to Session Chair/Co-Chair
4:05 p.m. – 4:25 p.m.	Alan Pollack, M.D., Ph.D., University of Miami, Consortium of Imaging and Biomarkers
4:25 p.m. – 4:45 p.m.	Brian Wolpin, M.D., M.P.H., Dana-Farber Cancer Institute, Pancreatic Cancer Detection Consortium
4:45 p.m. – 5:05 p.m.	Stephen Pandol, M.D., Cedars- Sinai, Chronic Pancreatitis, Diabetes and Pancreatic Cancer Consortium
5:05 p.m. – 5:15 p.m.	Barbara Kenner, Ph.D., Kenner Family Research Fund
5:15 p.m. – 5:30 p.m.	Cancer Research UK's Strategy and Activities in Early Detection Research David Crosby Ph.D., Cancer Research UK
5:30 p.m.	Adjourn for the Day
7:00 p.m. – 9:00 p.m . White Oak B	Discussion on International Collaborations

Cancer Biomarkers in Precision Medicine March 6-8, 2018

Bethesda North Marriott Hotel & Conference Center Bethesda, Maryland

Thursday, March 8, 2018

7:30 a.m. – 8:30 a.m. Registration Ballroom Foyer

Joint Meeting of the EDRN and Molecular and Cellular Characterization of Screen-Detected Lesions (MCL) Consortium

8:30 a.m. - 3:40 p.m.

Salon F-H

On Early Cancer Detection and

Overdiagnosis

8:30 a.m. – 8:40 a.m.

Welcome and Introductory Remarks

Dinah Singer, Ph.D., Director, Division of
Cancer Biology, National Cancer Institute

Barnett S. Kramer, M.D., M.P.H., Director, Division of Cancer Prevention, National Cancer Institute

8:40 a.m. - 9:05 a.m. Plenary Lecture

GRAIL's Approach to Early Cancer Detection Elizabeth Mansfield, Ph.D., GRAIL O&A

9:05 a.m. – 9:10 a.m. O8

9:10 a.m. - 10:50 a.m. Prostate Cancer

Session Chairs

- Shiv Srivastava, Ph.D., Center for Prostate Disease Research
- Angelo DeMarzo, M.D., Ph.D., Johns Hopkins University

9:10 a.m. – 9:30 a.m. Genomic Studies of Prostate Cancer Evolution
James D. Brooks, M.D., Stanford University
Robert West, M.D., Ph.D. Stanford University
9:30 a.m. – 9:35 a.m.
O&A

.00 и.п. 9.00 и.п. Q....

9:35 a.m. – 9:55 a.m. <u>Prostate Cancer Precursor Lesions: Rethinking</u>

What We Know

Angelo DeMarzo, M.D., Ph.D., and Srinivasan Yegnasubramanian, M.D., Ph.D., Johns Hopkins University

Cancer Biomarkers in Precision Medicine March 6-8, 2018

Bethesda North Marriott Hotel & Conference Center Bethesda, Maryland

Thursday, March 8, 2018 Continued

Interdisciplinary Organ-Specific Research on Early Cancer Detection and Overdiagnosis - Prostate Cancer -Continued

9:55 a.m. – 10:00 a.m. Salon F-H	Q&A
10:00 a.m. – 10:20 a.m.	A Targeted Proteomics Strategy for the Development of Prostate Cancer Liquid- Biopsies John Semmes, Ph.D., Eastern Virginia Medical School
10:20 a.m. – 10:25 a.m.	Q&A
10:25 a.m. – 10:45 a.m.	Interrogating the Urinary Transcriptome to Refine Prostate Cancer Detection Martin Sanda, M.D., Emory University
10:45 a.m. – 10:50 a.m.	Q&A
10:50 a.m 11:10 a.m.	Break
11:10 a.m 12:50 p.m.	Breast Cancer
Salon F-H	 Session Chairs Jeff Marks, Ph.D., Duke University Medical School Alexander Borowsky, M.D., University of California, Davis
Salon F-H 11:10 a.m. – 11:30 a.m.	 Jeff Marks, Ph.D., Duke University Medical School Alexander Borowsky, M.D., University of
	 Jeff Marks, Ph.D., Duke University Medical School Alexander Borowsky, M.D., University of California, Davis Understanding the Landscape of DCIS Laura Esserman, M.D., M.B.A., University of California, San Francisco Michael Campbell, Ph.D., University of
11:10 a.m. – 11:30 a.m.	 Jeff Marks, Ph.D., Duke University Medical School Alexander Borowsky, M.D., University of California, Davis Understanding the Landscape of DCIS Laura Esserman, M.D., M.B.A., University of California, San Francisco Michael Campbell, Ph.D., University of California, San Francisco

Cancer Biomarkers in Precision Medicine March 6-8, 2018

Bethesda North Marriott Hotel & Conference Center Bethesda, Maryland

Thursday, March 8, 2018 Continued

Interdisciplinary Organ-Specific Research on Early Cancer Detection and Overdiagnosis - Breast Cancer - Continued

12:00 p.m. – 12:20 p.m. Salon F-H	Unique Approach Combining Avatar Mice and Targeted Mass Spectrometry to Identify Blood Biomarkers for Early Detection of Breast Cancer Amanda Paulovich, M.D., Ph.D., Fred Hutchinson Cancer Research Center
12:20 p.m. – 12:25 p.m.	Q&A
12:25 p.m. – 12:45 p.m.	Breast Cancer: Integrating Imaging and Molecular Diagnostics Karen Anderson, M.D., Ph.D., Arizona State University
12:45 p.m. – 12:50 p.m.	Q&A
12:50 p.m. – 2:00 p.m.	Lunch (On Your Own)
2:00 p.m 3:40 p.m.	Lung Cancer
Salon F-H	Session Chairs O Harvey Pass, M.D., New York University School of Medicine O Avrum Spira, M.D., M.Sc., Boston University
Salon F-H 2:00 p.m. – 2:20 p.m.	 Session Chairs Harvey Pass, M.D., New York University School of Medicine Avrum Spira, M.D., M.Sc., Boston University Immunity and Inflammation in the Pathogenesis of Lung Cancer Steven Dubinett, M.D., University of California, Los Angeles
Salon F-H	 Session Chairs Harvey Pass, M.D., New York University School of Medicine Avrum Spira, M.D., M.Sc., Boston University Immunity and Inflammation in the Pathogenesis of Lung Cancer Steven Dubinett, M.D., University of
Salon F-H 2:00 p.m. – 2:20 p.m.	 Session Chairs Harvey Pass, M.D., New York University School of Medicine Avrum Spira, M.D., M.Sc., Boston University Immunity and Inflammation in the Pathogenesis of Lung Cancer Steven Dubinett, M.D., University of California, Los Angeles

Cancer Biomarkers in Precision Medicine March 6-8, 2018

Bethesda North Marriott Hotel & Conference Center Bethesda, Maryland

Thursday, March 8, 2018 Continued

5:00 p.m.

Interdisciplinary Organ-Specific Research on Early Cancer Detection and Overdiagnosis - Lung Cancer - Continued

2:50 p.m. – 3:10 p.m. Salon F-H	Whole Blood Gene Expression Can Accurately Distinguish Benign from Malignant Lung Nodules; Transitioning from Microarrays to the NanoString TM Platform Louise Showe, Ph.D., Wistar Institute
3:10 p.m. – 3:15 p.m.	Q&A
3:15 p.m. – 3:35 p.m.	Approaches to Improving DNA Methylation Detection James Herman, M.D., University of Pittsburgh School of Medicine
3:35 p.m. – 3:40 p.m.	Q&A
3:40 p.m 4:00 p.m.	Break
4:00 p.m. – 5:00 p.m. Salon F-H	Collaborative Opportunities between the EDRN and MCL (Leadership of these two consortia to present their vision for interacting with each other) Session Chairs Karen Anderson, M.D., Ph.D., Arizona State University

Adjourn EDRN/MCL Joint Meeting

of California, San Francisco

o Martin Sanda, M.D., Emory University

o Laura Esserman, M.D., M.B.A., University

o James Brooks, M.D., Stanford University